Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$86.72 USD
-0.70 (-0.80%)
Updated May 10, 2024 04:00 PM ET
After-Market: $86.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.70 (-0.80%)
Updated May 10, 2024 04:00 PM ET
After-Market: $86.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Zacks News
Strength Seen in Edwards Lifesciences (EW): Can Its 6.2% Jump Turn into More Strength?
by Zacks Equity Research
Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.
ITGR vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook
by Zacks Equity Research
Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Avanos Medical (AVNS) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences (EW) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Edwards Lifesciences (EW) Q3 Earnings Match Mark, Margins Dip
by Zacks Equity Research
Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.
CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings and sales beat estimates on the back of strong growth in the U.S and international markets. Gross margin improves.
West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect a strong demand for non-COVID-19 demand, especially HVP devices.
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include PepsiCo (PEP), The J.M. Smucker Co (SJM), AMC Entertainment (AMC), Edwards Lifesciences (EW) and Versus Systems (VS).
Edwards Lifesciences (EW) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Edwards Lifesciences (EW) Q3 Earnings Match Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 0.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More
by Urmimala Biswas
Medical Device companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, BIO, EW and LH fare this time.
5 Large-Cap Stocks to Buy Ahead of Q3 Earnings This Week
by Nalak Das
We have narrowed our search to five large-cap stocks that are set to declare third-quarter earnings results this week. These are: EW, VICI, VMC, GLPI, MBLY.
What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?
by Zacks Equity Research
Outside the United States, Edwards Lifesciences (EW) TAVR sales growth will likely be driven by broad-based adoption of the SAPIEN platform.
What's in Store for Option Care Health (OPCH) in Q3 Earnings?
by Zacks Equity Research
Option Care Health's (OPCH) Q3 results are likely to be driven by sustained strong utilization.
Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosted procedure sales.